XRME:F:F-Xtrackers MSCI USA ESG Screened UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 9.245

Change

+0.04 (+0.38)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-28 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.29 (+1.13%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.70 (+1.41%)

USD 115.04B
FRCJ:F UBS MSCI Japan Socially Respon..

+0.15 (+0.69%)

USD 83.57B
SXR8:F iShares Core S&P 500 UCITS ETF..

+7.24 (+1.46%)

USD 80.45B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.58 (+1.10%)

USD 76.57B
EUNL:F iShares Core MSCI World UCITS ..

+1.07 (+1.20%)

USD 72.04B
SXRZ:F iShares VII PLC - iShares Nikk..

+2.55 (+1.14%)

USD 58.19B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.17 (+1.17%)

USD 56.18B
VUSA:F Vanguard Funds Public Limited ..

+1.71 (+1.93%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+1.68 (+1.90%)

USD 49.95B

ETFs Containing XRME:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.20% 72% C 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.20% 70% C- 64% D
Trailing 12 Months  
Capital Gain 29.90% 85% B 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.90% 84% B 73% C
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.51% 75% C 72% C
Dividend Return 6.51% 74% C 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.15% 57% F 77% C+
Risk Adjusted Return 64.11% 92% A 90% A-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike